Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil added to pirfenidone in advanced idiopathic pulmonary fibrosis with probable group 3 pulmonary hypertension
2015-005131-40Phase 2Active
- Sponsor
- Roche
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH) comparing Sildenafil + Esbriet with Placebo + Esbriet (2 arms). Primary endpoints: Proportion of patients with disease progression over 52 weeks and Composite disease progression endpoint. Started Sep 2016; status: active.
02
Drugs
sildenafilpirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2015-005131-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005131-40.